Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9actual
Sites
1
Country
Sweden
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn Disease
Interventions
- Drug: AZD7798 — also filed as Study Drug
- Drug: [11C]AZ14132516 — also filed as Radioligand
Primary outcome
what the primary-completion date above is the date OFChange from baseline in intestinal SUV/SUVR
measured Weeks 13, 16, 20 and 24 (may vary between participants)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed